

Neuropeptide Y Receptor Type 2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/NF12E4AF01CCEN.html>

Date: March 2020

Pages: 34

Price: US\$ 3,500.00 (Single User License)

ID: NF12E4AF01CCEN

Abstracts

Neuropeptide Y Receptor Type 2 - Pipeline Review, H1 2020

SUMMARY

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. .The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity and Epilepsy.

The latest report Neuropeptide Y Receptor Type 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor

presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)

The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects

The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved
in Therapeutics Development

CombiGene AB

Gila Therapeutics Inc

Takeda Pharmaceutical Co Ltd

XL-protein GmbH

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles

CG-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GT-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYY-1119 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Discontinued Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones

Featured News & Press Releases

Jan 21, 2020: CombiGene receives the second instalment of EUR 1.21 million from Horizon 2020

Dec 19, 2019: Study in human brain tissue shows that NPY can suppress epileptic activity via Y2-receptor activation

Nov 18, 2019: CombiGene receives a second payment of EUR 1.21 million from Horizon 2020

Nov 06, 2019: CombiGene: Two significant steps towards the first human studies for CG01

Oct 14, 2019: CombiGene signs agreement with Cobra Biologics for production of candidate drug CG01

Sep 10, 2019: CombiGene chooses the CRO company Northern Biomedical Research as partner for upcoming preclinical biodistribution and safety studies

May 15, 2018: EU allocates EUR 3.6 million in funding for development of CombiGenes cutting-edge gene therapy technology

Feb 19, 2018: Final data from long-term study of CombiGene epilepsy treatment indicate clearly positive effects in the form of fewer and shorter seizures.

Dec 14, 2017: Study with brain tissue from human epilepsy patients confirms that brain cells express CombiGene's candidate drug CG01

Dec 06, 2017: Initial data from the long-term study on CombiGene's candidate drug for treating epilepsy indicate positive effects in the form of fewer seizures

Nov 09, 2012: Novel treatment strategies for epilepsy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by CombiGene AB, H1 2020

Pipeline by Gila Therapeutics Inc, H1 2020

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Pipeline by XL-protein GmbH, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

CombiGene AB

Gila Therapeutics Inc

Takeda Pharmaceutical Co Ltd

XL-protein GmbH

I would like to order

Product name: Neuropeptide Y Receptor Type 2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/NF12E4AF01CCEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NF12E4AF01CCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970